Major Depressive Disorder
Conditions
Keywords
MDD, escitalopram
Brief summary
This will be an open label study of escitalopram. Patients not responsive to citalopram will be switched directly to escitalopram. Patients will receive escalating doses of escitalopram up to a maximum of 50 mg until they either achieve remission (MADRS \<9) or fail to tolerate the dose.
Detailed description
Patients will receive escalating doses of escitalopram up to a maximum of 50 mg until they either achieve remission (MADRS \<9) or fail to tolerate the dose. Visit 1 - (Initial visit) - escitalopram 10 mg Visit 2 - (Week 2) - escitalopram 20 mg Visit 3 - (Week 4) - review visit Visit 4 - (Week 6) - MADRS \<12 - continue 20 mg MADRS \>12 - escitalopram 30 mg Visit 5 - (Week 8) - MADRS \<8 - continue current dose MADRS \>8 - escalate dose (20 mg to 30 mg or 30 mg to 35mg) Thereafter, Patients who have achieved remission will be maintained on the remission dosage and reviewed at four weekly intervals. At any subsequent visit where the MADRS is \>8 they will have a dosage increase Patients who have not achieved remission will have dosage escalated by 5 mg at two weekly intervals until remission, a maximum dose of 50 mg is achieved or the dosage is intolerable when they will be reduced to the previous tolerable dose. Patients will be followed up until eight months from their initial visit.
Interventions
DRUGescitalopram
Dose ranging up to 50mg
Sponsors
Community Pharmacology Services Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* written informed consent will be obtained from each patient * aged 18 to 65 inc * suffering from MDD as defined by DSM IV * have been taking citalopram in a dose of at least 20mg for at least six weeks * an inadequate response -- defined as failure to achieve a MADRS score of \<12
Exclusion criteria
* Significant other psychiatric disorder which would interfere with trial assessments. Co-morbid generalized anxiety disorder (GAD) and panic will be permitted where MDD is considered the primary diagnosis . * history of mania or bipolar disorder * Known contraindication for the use of citalopram or escitalopram. * Significant bleeding disorder * Prominent suicidal ideation (score more than 4 in the MADRS suicidal thoughts item) * Alcohol or substance dependence in the past 6 months * Major physical illness * Significant liver or renal function abnormality * Significant ECG abnormalities * Pregnant or lactating females * Inadequate contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patients achieving remission (MADRS<9). | 8 months |
Countries
United Kingdom
Outcome results
None listed